These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 827836)

  • 21. [Treatment of experimental tuberculosis in guinea pigs by continuous and intermittent regimen with special reference to ethambutol and rifampicin].
    Westfal I; Wiza J; Rudnicka M; Szymaczek-Meyer L
    Gruzlica; 1973 Jan; 41(1):1-8. PubMed ID: 4686876
    [No Abstract]   [Full Text] [Related]  

  • 22. [Experimental study of rifampicin and ethambutol].
    Kozulitsyna TI; Korotaev GA
    Probl Tuberk; 1971; 49(1):64-8. PubMed ID: 5576515
    [No Abstract]   [Full Text] [Related]  

  • 23. Rationale for chemotherapy of tuberculosis and current recommendations.
    Kumar L
    Indian Pediatr; 1992 Nov; 29(11):1337-9. PubMed ID: 1294486
    [No Abstract]   [Full Text] [Related]  

  • 24. Impact of iron loading on the activity of isoniazid or ethambutol in the treatment of murine tuberculosis.
    Lounis N; Maslo C; Truffot-Pernot C; Grosset J; Boelaert RJ
    Int J Tuberc Lung Dis; 2003 Jun; 7(6):575-9. PubMed ID: 12797701
    [TBL] [Abstract][Full Text] [Related]  

  • 25. First randomised trial of treatments for pulmonary disease caused by M avium intracellulare, M malmoense, and M xenopi in HIV negative patients: rifampicin, ethambutol and isoniazid versus rifampicin and ethambutol.
    Research Committee of the British Thoracic Society
    Thorax; 2001 Mar; 56(3):167-72. PubMed ID: 11182006
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential drug susceptibility of intracellular and extracellular tuberculosis, and the impact of P-glycoprotein.
    Hartkoorn RC; Chandler B; Owen A; Ward SA; Bertel Squire S; Back DJ; Khoo SH
    Tuberculosis (Edinb); 2007 May; 87(3):248-55. PubMed ID: 17258938
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Assessment of the use of a multicomponent drug in the treatment of new cases of pulmonary tuberculosis].
    Semenova OV
    Probl Tuberk Bolezn Legk; 2003; (11):22-5. PubMed ID: 14689793
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Effectiveness and problems of PZA-containing 6-month regimen for the treatment of new pulmonary tuberculosis patients].
    Wada M
    Kekkaku; 2001 Jan; 76(1):33-43. PubMed ID: 11211781
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gatifloxacin in combination with rifampicin in a murine tuberculosis model.
    Cynamon M; Sklaney MR; Shoen C
    J Antimicrob Chemother; 2007 Aug; 60(2):429-32. PubMed ID: 17561504
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Rifampicin in the treatment of active pulmonary tuberculosis. Controlled trial of isoniazid-rifampicin-thiocarlide versus isoniazid-streptomycin-thiocarlide in untreated tuberculosis. Treatment of relapses with the combination rifampicin-ethambutol-thiocarlide].
    Chioléro R
    Schweiz Med Wochenschr; 1974 Mar; 104(10):356-64. PubMed ID: 4206521
    [No Abstract]   [Full Text] [Related]  

  • 31. Anti-Mycobacterium tuberculosis activity of antituberculosis drugs and amoxicillin/clavulanate combination.
    Pagliotto AD; Caleffi-Ferracioli KR; Lopes MA; Baldin VP; Leite CQ; Pavan FR; Scodro RB; Siqueira VL; Cardoso RF
    J Microbiol Immunol Infect; 2016 Dec; 49(6):980-983. PubMed ID: 26454420
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rifampicin: a first line tuberculostatic drug. A critical review and appraisal.
    Saerens EJ
    Acta Tuberc Pneumol Belg; 1972; 63(6):516-28. PubMed ID: 4206441
    [No Abstract]   [Full Text] [Related]  

  • 33. Drug resistance in tuberculosis in Delhi: a 2 year profile (2001--2002).
    Negi SS; Gupta S; Lal S
    J Commun Dis; 2003 Jun; 35(2):74-81. PubMed ID: 15562952
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug susceptibility in Mycobacterium tuberculosis of a sample of patients in Guinea Bissau.
    Dias F; Michael SG; Hoffner SE; Martins L; Norberg R; Källenius G
    Tuber Lung Dis; 1993 Apr; 74(2):129-30. PubMed ID: 8324205
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Effect of isoniazid and rifampicin regimens on the liver of tuberculosis patients].
    Pilheu JA; De Salvo MC; Barcat JA
    Medicina (B Aires); 1979; 39(3):298-304. PubMed ID: 514051
    [No Abstract]   [Full Text] [Related]  

  • 36. The suitability of new drugs for intermittent chemotherapy of tuberculosis. An experimental study.
    Dickinson JM
    Scand J Respir Dis Suppl; 1969; 69():91-8. PubMed ID: 4190279
    [No Abstract]   [Full Text] [Related]  

  • 37. [Determination of resistance of Mycobacterium tuberculosis against isonicotinic acid hydrazide, streptomycin, para-aminosalicylic acid, ethionamide, ethambutol and rifampicin using the 32 P incorporation test].
    Reutgen H
    Acta Biol Med Ger; 1973; 30(3):309-16. PubMed ID: 4202698
    [No Abstract]   [Full Text] [Related]  

  • 38. Sulfamethoxazole enhances the antimycobacterial activity of rifampicin.
    Macingwana L; Baker B; Ngwane AH; Harper C; Cotton MF; Hesseling A; Diacon AH; van Helden P; Wiid I
    J Antimicrob Chemother; 2012 Dec; 67(12):2908-11. PubMed ID: 22875849
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessing Pharmacodynamic Interactions in Mice Using the Multistate Tuberculosis Pharmacometric and General Pharmacodynamic Interaction Models.
    Chen C; Wicha SG; de Knegt GJ; Ortega F; Alameda L; Sousa V; de Steenwinkel JEM; Simonsson USH
    CPT Pharmacometrics Syst Pharmacol; 2017 Nov; 6(11):787-797. PubMed ID: 28657202
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Delamanid Kills Dormant Mycobacteria
    Chen X; Hashizume H; Tomishige T; Nakamura I; Matsuba M; Fujiwara M; Kitamoto R; Hanaki E; Ohba Y; Matsumoto M
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28373190
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.